(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065959 A3

(51) International Patent Classification[7]: G01N 33/50

(21) International Application Number:
PCT/GB2004/000271

(22) International Filing Date: 23 January 2004 (23.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0301566.6	23 January 2003 (23.01.2003)	GB
60/457,533	25 March 2003 (25.03.2003)	US

(71) Applicant *(for all designated States except US)*: **EIRX THERAPEUTICS LIMITED** [IE/IE]; 2800 Cork Airport Business Park, Kinsale Road, Cork, Co. Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SEERY, Liam** [IE/IE]; EiRx Therapeutics Ltd, 2800 Cork Airport Business Park, Kinsale Road, Cork, Co. Cork (IE). **HAYES, Ian** [GB/IE]; EiRx Therapeutics Ltd, 2800 Cork Airport Business Park, Kinsale Road, Cork, Co. Cork (IE). **MURPHY, Finbarr** [IE/IE]; EiRx Therapeutics Ltd, 2800 Cork Airport Business Park, Kinsale Road, Cork, Co. Cork (IE).

(74) Agents: **FURLONG, Isla, Jane** et al.; D. Young & Co., 120 Holborn, London EC1N 2DY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
25 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: KINASES AND GPCRS INVOLVED IN APOPTOSIS

(57) Abstract: The present invention relates to a method of identifying an agent that modulates the function of an apoptosis-associated polypeptide having a sequence as set out in Table 1B, the method comprising: (a) providing a sample containing an apoptosis-associated polypeptide having a sequence as set out in Table 1B, and a candidate agent and incubating under conditions to permit binding of the candidate agent to the polypeptide; (b) measuring the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1B to the candidate agent in the sample; and (c) comparing the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1B to the candidate agent in the sample with the binding of the polypeptide having a sequence as set out in Table 1B to a control agent, wherein the control agent is known to not bind to the polypeptide having a sequence as set out in Table 1B; wherein an increase in the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1B to the candidate agent in the sample relative to the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1B to the control agent indicates that the candidate agent modulates the function of the apoptosis-associated polypeptide having a sequence as set out in Table 1B.

WO 2004/065959 A3